Vijayalak Pratha, MD
Gastroenterology · San Diego, CANPI 1992892707
Payments from drug & device makers
Across 337 payments — averaging $3467.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$268K
- Janssen Research & Development, LLC$175K
- Roche Products Limited$151K
- Chugai Pharmaceutical Co., Ltd.$131K
- Pfizer$123K
- AbbVie$76K
- plus $244K from 11 others
Across 9 payments — averaging $1536.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$10K
- Eli Lilly$4K
What the payments were for
- Food & beverage$25841%
- Education$36559%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 80 | $267,890 |
| Janssen Research & Development, LLC | 57 | $175,449 |
| Roche Products Limited | 59 | $151,290 |
| Chugai Pharmaceutical Co., Ltd. | 4 | $131,294 |
| Pfizer | 28 | $122,569 |
| AbbVie(2 entities) | 52 | $75,647 |
| Eli Lilly | 14 | $71,868 |
| E.r. Squibb & Sons, L.L.C. | 4 | $59,535 |
| Ironwood Pharmaceuticals, Inc | 8 | $51,999 |
| Teva Pharmaceuticals USA, Inc. | 6 | $38,197 |
| Phathom Pharmaceuticals, Inc. | 3 | $21,026 |
| Bausch Health US, LLC | 10 | $1,218 |
| Johnson & Johnson | 7 | $384 |
| AstraZeneca | 2 | $133 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $99 |
| Celltrion USA Inc. | 1 | $24 |
| Shield Therapeutics Inc | 1 | $15 |
How this compares
$1,168,638 in reported general payments places this provider in the 95th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 14 | $8,854 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 20 | $1,406 |
| Fluconazole | 14 | $207 |
| Levothyroxine Sodium | 12 | $6 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in San Diego
- Brigid BolandSan Diego$2.4M
- William SandbornSan Diego$2.2M
- Naveen GaraSan Diego$1.5M
- Michael BennettSan Diego$1.5M
- Taddese DestaSan Diego$1.4M
- Hyun KimSan Diego$1.3M
- David KunkelSan Diego$679K
- Peter WinkleCypress$116.7M
- Manuchehr DaraniSanta Ana$17.7M
- Jatinder PruthiLancaster$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.